Seriously, this is the best you clowns can do? Regurgitate the same paper over and over again. Omit mentioning the limitations of the Celgene study? Over 40% of patients dropped out of the study. The 44 patients out of the 107 patients discontinued because of adverse events with the chemo.
Let’s look out resection rates and compare the pair:- Celgene study reported only 7 patients with clear margin resection (R0). That’s less than 7% with clear margins. Check out the Oncosil PanCo study over 20% with clear margin resections.
You keep emphasising survival rates with Celgene. 18 months. That’s great. Oncosil has already over 16 months survival as of October 2019. PanCo study has not yet completed. Completion in June 2020. Reasonable to expect survival rates to increase when the trial is completed and reported by the Company.
Now go back to your Sirtex and other drug/device investments and start running for those hills when Oncosil comes after your market share. Admit it you clutzes, you’re afraid of the upcoming competition when Oncosil gets its regulatory approvals.
OSL Price at posting:
9.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)